• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Michael J. Fox Foundation announces research partners

Michael J. Fox Foundation announces research partners

July 12, 2013
CenterWatch Staff

Research projects from five biopharmaceutical companies in the U.S., Canada and Israel comprise the 2013 first half of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Participants' research projects are presented directly to industry groups that may wish to invest in further development. By connecting industry leaders with those studies ripe for investment, the Foundation aims to drive forward promising research in Parkinson's disease (PD) through the pipeline of drug development and eventually into patients' hands.

Non-confidential overviews of the selected MJFF-funded projects are shared with industry contacts and more broadly via MJFF's web site twice yearly in July and December. The five biopharmaceutical selected are Ceregene, MedGenesis, NeuroPhage Pharmaceuticals, Cynapsus Therapeutics and NeuroDerm.

Ceregene is studying clinical research on a gene delivery approach to neurotrophic factors. MedGenesis is investigating GDNF, a biological neurotrophic factor and potential disease-modifying therapy. MedGenesis has in-licensed the product from Amgen and has developed an enhanced delivery paradigm to overcome previous limitations. NeuroPhage Pharmaceuticals has completed a study of NPT002, a potential disease-modifying therapy for PD that targets alpha-synuclein. NPT002  binds, disaggregates and prevents the formation of multiple amyloidogenic structures. This novel approach has increased therapeutic potential as it targets both early amyloid assemblies as well as pre-existing aggregates.

While Ceregene, MedGenesis and NeuroPhage Pharmaceuticals study disease-modifying research, Cynapsus Therapeutics and NeuroDerm focus on symptomatic research. Cynapsus Therapeutics has developed APL-130277, a novel formulation of episodes in PD. NeuroDerm has completed clinical research on continuous administration of levodopa and carbidopa through a "pump-patch." This technology could maintain continuous and constant concentration of levodopa in the blood, which should significantly decrease motor fluctuations and possibly reverse dyskinesia.

To date, MJFF has funded $325 million in research, more than $84 million of which has been directed to over 185 projects.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing